natgillin/translations-raw huggingface dataset:
The pharmacokinetics of intravenous busulfan was studied in 124 evaluable patients following a 2-hour intravenous infusion for a total of 16 doses over four days.
Farmakokinetiko intravensko uporabljenega busulfana so preučevali pri 124 bolnikih, ki jih je bilo možno oceniti, po 2-urni intravenski infuziji, do skupno 16 odmerkov v obdobju 4 dni.
However, more than 500 patients aged ≥ 55 years were reported in publications with FB conditioning regimens, yielding efficacy outcomes similar to younger patients.
Vendar objave o pripravljalnih shemah FB poročajo o več kot 500 bolnikih, starih ≥ 55 let; dosežena učinkovitost je bila podobna kot pri mlajših bolnikih.
Increase of lactate dehydrogenase in the blood.
Povišanje laktat-dehidrogenaze v krvi.
Busulfan should not be given by rapid intravenous, bolus or peripheral injection.
Busulfana ne smete uporabiti v obliki hitre intravenske injekcije, bolusa ali periferne injekcije.
Nutrition: loss of appetite, decrease in magnesium, calcium, potassium, phosphate, albumine in blood, and increase in blood sugar.
Prehrana: izguba teka, zmanjšanje količine magnezija, kalcija, kalija, fosfata in albumina v krvi ter povišanje sladkorja v krvi.
The incidence of each adverse reactions presented in the following table has been defined according to the highest incidence observed in published clinical trials in RIC regimen for which the population treated with FB was clearly identified, whatever the schedules of busulfan administrations and endpoints.
Incidenca vsakega neželenega učinka, prikazanega v naslednji preglednici, je opredeljena glede na najvišjo incidenco, opaženo v objavljenih kliničnih preskušanjih s shemo RIC, kjer je bila s FB zdravljena populacija jasno identificirana, ne glede na uporabljeno shemo odmerjanja busulfana ali na opazovane dogodke.
Compared to the four times a day regimen, the once-daily regimen is characterized by a higher peak concentration, no drug accumulation and a wash out period (without circulating busulfan concentration) between consecutive administrations.
V primerjavi s shemo odmerjanja štirikrat na dan, dosega shema odmerjanja enkrat dnevno višjo najvišjo koncentracijo, je ne spremlja kopičenje zdravila in ima obdobje izpiranja (brez koncentracije busulfana v obtoku) med zaporednimi uporabami.
Data from a recently completed prospective multicentre phase 2 study including 80 patients, aged 18 to 65 years old, diagnosed with different hematologic malignancies who underwent allo-HCT with an FB (3 days of busulfan) reduced intensity conditioning regimen became available.
Na voljo so podatki nedavno dokončane prospektivne multicentrične študije 2. faze, ki je vključevala 80 bolnikov v starosti od 18 do 65 let, z diagnosticiranimi različnimi hematološkimi malignomi, in opravljeno homologno transplantacijo hematopoetskih celic s pripravljalno shemo FB zmanjšane intenzivnosti (3 dnevi busulfana).
Blood: decrease of blood circulating cells (red and white) and platelets.
Kri: zmanjšanje števila krvnih celic (rdečih in belih) ter trombocitov v krvnem obtoku.
Since busulfan is mainly metabolized through the liver, caution should be observed when busulfan is used in patients with pre-existing impairment of liver function, especially in those with severe hepatic impairment.
Ker se busulfan v glavnem presnavlja v jetrih, je priporočljiva posebna previdnost pri uporabi busulfana pri bolnikih z že okvarjeno jetrno funkcijo, zlasti pri tistih s hudo okvaro jeter.
No specific clinical trial was carried out to assess drug-drug interaction between intravenous busulfan and itraconazole or metronidazole.
Specifičnih kliničnih preskušanj za oceno medsebojne interakcije med intravensko uporabljenim busulfanom in itrakonazolom ali metronidazolom niso izvedli.
The most serious side effects of busulfan therapy or the transplant procedure may include decrease in circulating blood cell counts (intended effect of the medicine to prepare you for your transplant infusion), infection, liver disorders including blocking of a liver vein, graft versus host disease (the graft attacks your body) and pulmonary complications.
Najresnejši neželeni učinki zdravljenja z busulfanom ali postopka presaditve so zmanjšanje števila krvnih celic v krvnem obtoku (želeni učinek zdravila, ki vas pripravi na transplantacijsko infuzijo), okužba, motnje v delovanju jeter (vključno z blokirano jetrno veno), reakcija presadka proti gostitelju (presadek napade vaše telo) in pljučni zapleti.
Y: body weight of the patient in kg D: dose of busulfan (see section 4.2)
Y: telesna masa bolnika v kilogramih D: odmerek busulfana (glejte poglavje 4.2)
On the basis of human data, busulfan has been classified by the International Agency for Research on Cancer (IARC) as a human carcinogen.
Na podlagi podatkov o ljudeh, je Mednarodna agencija za raziskave rakavih obolenj (International Agency for Research on Cancer (IARC)) uvrstila busulfan med človeške kancerogene.
Fast and complete engraftment rates in 80-100% of patients were reported in the majority of studies.
V večini študij so poročali o hitri in popolni vsaditvi pri od 80 do 100 % bolnikov.
In these studies, a total of 1574 patients received FB as a reduced intensity conditioning (RIC) regimen prior to haematopoietic progenitor cell transplantation.
V teh študijah je skupno 1.574 bolnikov dobivalo FB v pripravljalni shemi RIC pred transplantacijo hematopoetskih progenitorskih celic.
Busulfan is for intravenous use.
Busulfan je namenjen intravenski uporabi.
Doses of 400 mg/kg/day DMA administered during organogenesis caused significant developmental anomalies.
Med organogenezo so odmerki DMA 400 mg/kg/dan povzročili pomembne anomalije v razvoju.
Chemical and physical in-use stability after dilution in glucose 5% or sodium chloride 9 mg/ml (0.9%) solution for injection has been demonstrated for 8 hours (including infusion time) after dilution when stored at 25°C ± 2°C or 12 hours after dilution when stored at 2°C-8°C followed by 3 hours stored at 25°C ± 2°C (including infusion time).
Kemijska in fizikalna stabilnost med uporabo, po redčenju s 5 % raztopino glukoze ali 0,9 % raztopino natrijevega klorida (9 mg/ml) za injiciranje, sta dokazani do 8 ur (vključno s časom infuzije) po redčenju, če je bila raztopina shranjena pri temperaturi 25 °C ± 2 °C, ali do 12 ur po redčenju, če je bila raztopina shranjena pri temperaturi med 2 in 8 °C in nato 3 ure pri temperaturi 25 °C ± 2 °C (vključno s časom infuzije).
Documentation on the safety and efficacy of busulfan in combination with fludarabine (FB) prior to allogeneic HPCT derives from the literature review of 7 published studies involving 731 patients with myeloid and lymphoid malignancies reporting the use of intravenous busulfan infused once daily instead of four doses per day.
Dokumentacija o varnosti in učinkovitosti busulfana v kombinaciji s fludarabinom (FB) pred homologno transplantacijo hematopoetskih progenitorskih celic izvira iz pregleda literature 7 objavljenih študij, ki so zajele 731 bolnikov z mieloičnimi in limfatičnimi malignomi in so uporabljale intravensko infundirani busulfan enkrat dnevno, namesto štirih odmerkov na dan.
It seems that the recommended intravenous busulfan dose administered either as an individual infusion (3.2 mg/kg) or into 4 divided infusions (0.8 mg/kg) provided equivalent daily plasma exposure with similar both inter-and intrapatient variability.
Zdi se, da je priporočeni odmerek intravenskega busulfana v posamezni infuziji (3,2 mg/kg) ali v 4 deljenih infuzijah (0,8 mg/kg) zagotovil enakovredno dnevno izpostavljenost v plazmi, s podobno inter- in intraindividualno variabilnostjo.
- 12 hours after dilution when stored at 2°C-8°C followed by 3 hours stored at 25°C ± 2°C (including infusion time).
- do 12 ur po redčenju, če je bila raztopina shranjena pri temperaturi med 2 in 8 °C in nato 3 ure pri temperaturi 25 °C ± 2 °C (vključno s časom infuzije).
The literature on busulfan suggests a therapeutic AUC window between 900 and 1500 µmol/L.minute per administration (equivalent to a daily exposure between 3600 and 6000 µmol/L.minute).
Literatura o busulfanu priporoča terapevtsko AUC območje med 900 in 1.500 µmol/l·min, na uporabo (kar ustreza dnevni izpostavljenosti med 3.600 in 6.000 µmol/l.
- The other ingredients are dimethylacetamide and macrogol 400.
- Pomožni snovi sta dimetilacetamid in makrogol 400.
Only a clear solution without particles should be used.
Uporabiti smete le bistro raztopino, brez delcev.
In this regard, for children < 9 kg, a monitoring of the plasma concentrations of busulfan (therapeutic drug monitoring) for dose-adjustment may improve the busulfan targeting performance, especially in extremely young children and neonates.
Zaradi tega je priporočljivo pri otrocih s telesno maso < 9 kg spremljati plazemske koncentracije busulfana (terapevtsko spremljanje zdravila), ker lahko z uravnavanjem odmerka izboljšamo ciljno učinkovitost busulfana, kar še posebej velja za izjemno majhne otroke in novorojenčke.
PK/PD relationship was observed between stomatitis and AUCs in autologous patients and between bilirubin increase and AUCs in a combined autologous and allogeneic patient analysis.
FK/FD razmerje so opazili med stomatitisom in vrednostmi AUC pri avtolognih bolnikih, ter med povišanjem vrednosti bilirubina in vrednostmi AUC pri analizi združenih podatkov avtolognih in alogenskih bolnikov.
Gastro-intestinal: bleeding in the stomach and/or the gut.
Prebavila: krvavitve v želodcu in/ali črevesju.
A total of 14 patients (50%) experienced a-GVHD.
Skupno 14 bolnikov (50 %) je izkusilo aGVHD.
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 1 vial of 10 ml.
FARMACEVTSKA OBLIKA IN VSEBINA koncentrat za raztopino za infundiranje 1 viala z 10 ml.
Gastrointestinal disorders The highest frequency of nausea and vomiting was 59.1% and the highest frequency of stomatitis was
Bolezni prebavil: Največja pogostnost navzee in bruhanja je bila 59,1 % in največja pogostnost stomatitisa 11 %.
Respiratory: decrease in blood oxygen.
Dihala: zmanjšana koncentracija kisika v krvi.
The incidence of a-GVHD grades I-II was 13% (8/61), while the incidence of grade III-IV was 5% (3/61).
Pojavnost aGVHD stopnje I-II je bila 13 % (8/61), medtem ko je bila pojavnost stopnje III-IV 5 % (3/61).
The entire prescribed busulfan dose should be delivered over two or three hours depending on the conditioning regimen.
Infuzija celotnega predpisanega odmerka busulfana mora trajati dve ali tri ure, odvisno od pripravljalne sheme.
The incidence of a-GVHD grades I-II was 46.4% (13/28), while the incidence of grade III-IV was 3.6% (1/28).
Pojavnost aGVHD stopnje I-II je bila 46,4 % (13/28), medtem ko je bila pojavnost stopnje IIIIV 3,6 % (1/28).
Busulfan must not be infused concomitantly with another intravenous solution.
Busulfan se ne sme uporabljati sočasno z drugimi intravenskimi raztopinami.
It is recommended to administer anticonvulsants 12 h prior to busulfan to 24 h after the last dose of busulfan.
Antikonvulzive je priporočeno dajati od 12 ur pred odmerkom busulfana do 24 ur po zadnjem odmerku.
There have been two reports that busulfan is dialyzable, thus dialysis should be considered in the case of an overdose.
V dveh poročilih je omenjeno, da se busulfan dializira, zato je v primeru prevelikega odmerjanja primerno pretehtati tudi možnost dialize.
Nervous system: confusion, nervous system disorders.
Živčni sistem: zmedenost, bolezni živčevja.
D: dose of busulfan (see SPC section 4.2)
D: odmerek busulfana (glejte poglavje 4.2)
Busulfan in combination with cyclophosphamide or melphalan Adverse reactions reported both in adults and paediatric patients as more than an isolated case are listed below, by system organ class and by frequency.
Busulfan v kombinaciji s ciklofosfamidom ali melfalanom Neželeni učinki pri odraslih in pediatričnih bolnikih, o katerih so poročali pri več kot enem primeru, so po organskih sistemih in po pogostnosti razvrščeni spodaj.
(A ml Busulfan Fresenius Kabi) x (10) = B ml of diluent
(A ml zdravila Busulfan Fresenius Kabi) x (10) = B ml redčila
Menopausal symptoms and female infertility.
Simptomi menopavze in neplodnost pri ženskah.
Brain abscess, Inflammation of the skin, generalised infection.
Možganski absces, vnetje kože, splošna okužba.
QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of concentrate contains 6 mg of busulfan (60 mg in 10 ml).
KAKOVOSTNA IN KOLIČINSKA SESTAVA En ml koncentrata vsebuje 6 mg busulfana (60 mg v 10 ml).
OTHER SPECIAL WARNING IF NECESSARY Cytotoxic
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Citotoksično zdravilo.
Occurrence of VOD was not related to overexposure.
Pogostnost veno-okluzivne bolezni (VOD) ni bila povezana s preveliko izpostavljenostjo.
Polycarbonate syringes must not be used with busulfan.
Pri uporabi busulfana se ne sme uporabljati polikarbonatnih brizg.
At 2 years, the cumulative incidence of NRM was 11.3% (95%CI, 5.5-19.3%), and that of relapse or progression from allo-HCT was 43.8% (95CI, 31.1-55.7%).
Po dveh letih je bila kumulativna incidenca UNP 11,3 % (95 % IZ: od 5,5 do 19,3 %) in recidiva ali napredovanja od homologne transplantacije hematopoetskih celic 43,8 % (95 % IZ: od 31,1 do 55,7 %).
followed by: - 4 cycles of 50 mg/kg body weight (BW) cyclophosphamide (BuCy4) or - one administration of 140 mg/m² melphalan (BuMel) initiated for at least 24 hours following the 16th dose of busulfan (see section 4.5).
Temu sledijo: - 4 cikli po 50 mg/kg telesne mase (TM) ciklofosfamida (BuCy4) ali - en odmerek 140 mg/m2 melfalana (BuMel), ki se začnejo vsaj 24 ur po 16. odmerku busulfana (glejte poglavje 4.5).
Leukaemia patients treated with busulfan developed many different cytological abnormalities, and some developed carcinomas.
Pri bolnikih z levkemijo, ki so bili zdravljeni z busulfanom, se je razvilo mnogo različnih citoloških sprememb, pri nekaterih je nastal karcinom.
Severe granulocytopenia, thrombocytopenia, anaemia, or any combination thereof may develop.
Razvije se lahko huda granulocitopenija, trombocitopenija, anemija ali katera koli kombinacija naštetega.
The World Health Organisation has concluded that there is a causal relationship between busulfan exposure and cancer.
Svetovna zdravstvena organizacija (WHO) je ugotovila, da obstaja vzročna povezava med izpostavljenostjo busulfanu in rakom.
Busulfan Fresenius Kabi is a potent cytotoxic medicine that results in profound decrease of blood cells.
Zdravilo Busulfan Fresenius Kabi je močno citotoksično zdravilo, ki zelo zmanjša število krvnih celic.
Caution should be exercised when using paracetamol prior to (less than 72 hours) or concurrently with busulfan due to a possible decrease in the metabolism of busulfan (See section 4.5).
Pri predhodni (manj kot 72-urni) ali sočasni uporabi paracetamola z busulfanom morate biti previdni zaradi možne zmanjšane presnove busulfana (glejte poglavje 4.5).
Busulfan in combination with fludarabine (FB) In adults The recommended dose and schedule of administration is: - fludarabine administered as a single daily one-hour infusion at 30 mg/m² for 5 consecutive days or 40 mg/m² for 4 consecutive days.
Busulfan v kombinaciji s fludarabinom (FB) Odrasli Priporočeni odmerek in razpored uporabe sta: - Fludarabin v enourni infuziji v enkratnem dnevnem odmerku 30 mg/m2, 5 dni zapored ali 40 mg/m2, 4 dni zapored.
The concomitant systemic administration of phenytoin to patients receiving high-dose of oral busulfan has been reported to increase busulfan clearance, due to induction of glutathion-S-transferase whereas no interaction has been reported when benzodiazepines such as diazepam, clonazepam or lorazepam have been used to prevent seizures with high-dose busulfan.
Poročali so, da sočasna sistemska uporaba fenitoina pri bolnikih, ki prejemajo visoke peroralne odmerke busulfana, poveča očistek busulfana zaradi indukcije glutation-S-transferaze,medtem ko pri uporabi benzodiazepinov, kot so diazepam, klonazepam ali lorazepam, za preprečevanje epileptičnih napadov pri visokih odmerkih busulfana, niso poročali o nikakršnih interakcijah.
Busulfan administration should be supervised by a physician experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.
Uporabo busulfana mora nadzorovati zdravnik, izkušen v pripravljalnih terapijah pred transplantacijo hematopoetskih progenitorskih celic.
WHO has concluded that there is a causal relationship between busulfan exposure and cancer.
WHO je ugotovila, da obstaja vzročno razmerje med izpostavljenostjo busulfanu in rakom.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements for cytotoxic medicinal products.
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi za citotoksična zdravila.
You should tell your doctor: - if you have a liver, kidney, heart or lung problem, - if you have a history of seizures, - if you are currently taking other medicines.
- imate težave z jetri, ledvicami, srcem ali pljuči, - ste kdaj imeli epileptične napade, - trenutno jemljete druga zdravila.
During clinical trials with intravenous busulfan administered as 0.80 mg/kg four-times daily, 90% of patients AUCs were below the upper AUC limit (1500 µmol/L.minute) and at least 80% were within the targeted therapeutic window (900 - 1500 µmol/L.minute).
Med kliničnimi preskušanji z intravensko uporabo busulfana v odmerku 0,80 mg/kg, štirikrat dnevno, je bilo 90 % bolnikov pod zgornjo mejo AUC (površine pod krivuljo) (1.500 µmol/l·min) in vsaj 80 % bolnikov je bilo znotraj ciljnega terapevtskega območja (med 900 in 1.500 µmo/l·min).
Patients received a conditioning regimen based on the administration of fludarabine immediately followed by single daily dose of 3.2 mg/kg busulfan over 2 or 3 consecutive days.
Bolniki so prejemali pripravljalno shemo na podlagi uporabe fludarabina, ki mu je takoj sledil enkraten dnevni odmerek 3,2 mg/kg busulfana, v 2 ali 3 dneh zapored.
The 2-year OS rate was 61.9% (95%CI, 51.1-72.7%)].
Dveletni delež celokupnega preživetja je bil 61,9 % (95 % IZ: od 51,1 do 72,7 %).
Interstitial lung disease**
Intersticijska bolezen pljuč**
Documentation on the safety and efficacy of busulfan in combination with cyclophosphamide in the BuCy2 regimen prior to conventional allogeneic and/or autologous HPCT derives from two clinical trials (OMC-BUS-4 and OMC-BUS-3).
Dokumentacija o varnosti in učinkovitosti busulfana v kombinaciji s ciklofosfamidom v terapiji BuCy2 pred konvencionalno alogensko in/ali avtologno HPCT izhaja iz dveh kliničnih preskušanj (OMC-BUS4 in OMC-BUS-3).
Busulfan following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen.
Busulfan po fludarabinu (FB) je indiciran kot pripravljalno zdravljenje pred transplantacijo hematopoetskih progenitorskih celic (HPCT) pri odraslih bolnikih, ki so kandidati za pripravljalno shemo zmanjšane intenzivnosti (RIC - reduced-intensity conditioning).
The analysis of data through a population pharmacokinetic method indicated no difference on intravenous busulfan clearance between phenytoin and clonazepam based therapy and therefore similar busulfan plasma exposures were achieved whatever the type of seizure prophylaxis.
Analiza podatkov z metodo populacijske farmakokinetike je pokazala, da ni razlik v očistku intravensko uporabljenega busulfana pri zdravljenju, ki temelji na fenitoinu ali klonazepamu, torej so pri obeh vrstah preprečevanja epileptičnih napadov bile dosežene podobne izpostavitve busulfanu v plazmi.
In adults Busulfan Fresenius Kabi is used in combination with cyclophosphamide or fludarabine.
Pri odraslih se zdravilo Busulfan Fresenius Kabi uporablja v kombinaciji s ciklofosfamidom ali fludarabinom.
The malformations included serious heart and/or major vessels anomalies: a common truncus arteriosis and no ductus arteriosis, coarctation of the pulmonary trunk and the pulmonary arteries, intraventricular defects of the heart.
Med malformacije so sodile resne anomalije srca in/ali velikih žil: truncus arteriosis in odsotnost Botallovega voda, koarktacija pljučnega debla in pljučnih arterij ter intraventrikularne okvare srca.
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 8 vials of 10 ml 60 mg per vial
FARMACEVTSKA OBLIKA IN VSEBINA koncentrat za raztopino za infundiranje 8 vial po 10 ml
DMA decreases fertility in male and female rodents.
DMA zmanjšuje plodnost samcev in samic pri glodavcih.
- Busulfan will be administered at 3.2 mg/kg as a single daily three-hour infusion immediately after fludarabine for 2 or 3 consecutive days.
- Busulfan je treba uporabiti v enkratnem dnevnem odmerku 3,2 mg/kg v 3-urni infuziji, takoj po fludarabinu, 2 ali 3 dni zapored.
You will receive this preparative medicine before receiving a transplant of either bone marrow or haematopoietic progenitor cell.
To zdravilo boste prejeli kot pripravljalno terapijo pred presaditvijo kostnega mozga ali krvotvornih progenitorskih celic.
Veno occlusive disease (VOD) was reported in 15% (4/27) and 7% (2/28) of the autologous and allogenic transplant respectively.
Pri 15 % (4/27) bolnikov z avtologno in pri 7 % (2/28) bolnikov z alogensko transplantacijo so poročali o veno-okluzivni bolezni (VOD).
A single s.c. dose of 2.2 g/kg administered on gestation day 4 terminated pregnancy in 100% of tested hamster.
Enkratni subkutani odmerek 2,2 g/kg v četrtem dnevu brejosti je prekinil brejost pri 100 % testiranih samic hrčkov.
Thrombocytopenia (< 25x109/l or requiring platelet transfusion) occurred at a median of 5-6 days in 98% of patients.
Trombocitopenija (< 25 x 109/l ali zahtevana transfuzija trombocitov) se je pojavila mediano 5-6 dni pri 98 % bolnikov.
Busulfan is metabolised mainly through conjugation with glutathione (spontaneous and glutathione-S-transferase mediated).
Busulfan se presnavlja predvsem preko konjugacije z glutationom (spontano ali pa pod vplivom glutation-S-transferaze).
* reported in post-marketing experience ** include haemorrhagic cystitis induced by viral infection
* objavljeno v obdobju, ko je zdravilo že na trgu ** vključuje hemoragični cistitis, povzročen z virusno okužbo
Chemical and physical in-use stability after dilution in glucose 5% or sodium chloride 9 mg/ml (0.9%) solution for injection has been demonstrated for:
Kemijska in fizikalna stabilnost med uporabo, po redčenju s 5 % raztopino glukoze ali 0,9 % raztopino natrijevega klorida (9 mg/ml) za injiciranje, sta dokazani:
OUTER CARTON containing 8 vials
PODATKI NA ZUNANJI OVOJNINI ZUNANJI KARTON, ki vsebuje 8 vial
In adult and paediatric studies, patients received either phenytoin or benzodiazepines as seizure prophylaxis treatment (see sections 4.4 and 4.5).
V študijah pri odrasli in pediatrični populaciji so bolniki kot profilakso proti epileptičnim napadom preventivno prejemali fenitoin ali benzodiazepine (glejte poglavji 4.4 in 4.5).
- the contents of the syringe must be dispensed into an intravenous bag (or syringe) which already contains the calculated amount of the selected diluent.
- vsebino brizge morate prestaviti v vrečko (ali brizgo) za intravensko uporabo, v katero ste prej že dali izračunano količino izbranega redčila.
Serious toxicities involving the hepatic and respiratory systems were considered as expected consequences of the conditioning regimen and transplant process.
Resne toksične učinke, ki vplivajo na jetrni in respiratorni sistem, so smatrali kot pričakovane posledice pripravljalne terapije in transplantacijskega procesa.
Serious toxicities involving the haematologic, hepatic and respiratory systems were considered as expected consequences of the conditioning regimen and transplant process.
Resne toksične učinke, ki vplivajo na hematološki, jetrni in respiratorni sistem, so upoštevali kot pričakovane posledice pripravljalne terapije in transplantacijskega procesa.
• Quantity of Busulfan Fresenius Kabi:
• Količina zdravila Busulfan Fresenius Kabi:
In adults, for the FB regimen, published studies did not report any mutual drug-drug interaction between intravenous busulfan and fludarabine.
V objavljenih študijah s shemo FB pri odraslih niso zabeležili nobenega medsebojnega delovanja med intravenskim busulfanom in fludarabinom.